220 related articles for article (PubMed ID: 38302471)
41. Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.
Bhardwaj M; Weigl K; Tikk K; Holland-Letz T; Schrotz-King P; Borchers CH; Brenner H
Eur J Cancer; 2020 Mar; 127():30-40. PubMed ID: 31972396
[TBL] [Abstract][Full Text] [Related]
42. Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells.
Lv Y; Wang W; Liu Y; Yi B; Chu T; Feng Z; Liu J; Wan X; Wang Y
Clin Exp Metastasis; 2023 Aug; 40(4):339-356. PubMed ID: 37326719
[TBL] [Abstract][Full Text] [Related]
43. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
[TBL] [Abstract][Full Text] [Related]
44. Identification of S100A8 and S100A9 as serological markers for colorectal cancer.
Kim HJ; Kang HJ; Lee H; Lee ST; Yu MH; Kim H; Lee C
J Proteome Res; 2009 Mar; 8(3):1368-79. PubMed ID: 19186948
[TBL] [Abstract][Full Text] [Related]
45. Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment.
Otsuki Y; Ouchi K; Takahashi S; Sasaki K; Sakamoto Y; Okita A; Ishioka C
Cancer Sci; 2022 Sep; 113(9):3221-3233. PubMed ID: 35403373
[TBL] [Abstract][Full Text] [Related]
46. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
47. Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature.
Guo S; Chen D; Huang X; Cai J; Wery JP; Li QX
Oncotarget; 2016 Aug; 7(31):50575-50581. PubMed ID: 27409671
[TBL] [Abstract][Full Text] [Related]
48. Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer.
Strohkamp S; Gemoll T; Humborg S; Hartwig S; Lehr S; Freitag-Wolf S; Becker S; Franzén B; Pries R; Wollenberg B; Roblick UJ; Bruch HP; Keck T; Auer G; Habermann JK
Cell Mol Life Sci; 2018 Jan; 75(2):323-334. PubMed ID: 28849249
[TBL] [Abstract][Full Text] [Related]
49. Proteomics for discovery of candidate colorectal cancer biomarkers.
Alvarez-Chaver P; Otero-Estévez O; Páez de la Cadena M; Rodríguez-Berrocal FJ; Martínez-Zorzano VS
World J Gastroenterol; 2014 Apr; 20(14):3804-24. PubMed ID: 24744574
[TBL] [Abstract][Full Text] [Related]
50. Proteomic analysis of minute amount of colonic biopsies by enteroscopy sampling.
Liu X; Xu Y; Meng Q; Zheng Q; Wu J; Wang C; Jia W; Figeys D; Chang Y; Zhou H
Biochem Biophys Res Commun; 2016 Aug; 476(4):286-292. PubMed ID: 27230957
[TBL] [Abstract][Full Text] [Related]
51. Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.
Liu R; Zhao X; Guo W; Huang M; Qiu L; Zhang W; Zhang Z; Li W; Zhu X; Chen Z
Clin Transl Oncol; 2020 Jun; 22(6):928-934. PubMed ID: 31571151
[TBL] [Abstract][Full Text] [Related]
52. Proteomic Profiling for Colorectal Cancer Biomarker Discovery.
Álvarez-Chaver P; De Chiara L; Martínez-Zorzano VS
Methods Mol Biol; 2018; 1765():241-269. PubMed ID: 29589313
[TBL] [Abstract][Full Text] [Related]
53. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours.
López-Sánchez LM; Jiménez-Izquierdo R; Peñarando J; Mena R; Guil-Luna S; Toledano M; Conde F; Villar C; Díaz C; Ortea I; De la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
J Cell Mol Med; 2019 Dec; 23(12):8219-8232. PubMed ID: 31560832
[TBL] [Abstract][Full Text] [Related]
54. Molecular alterations and biomarkers in colorectal cancer.
Grady WM; Pritchard CC
Toxicol Pathol; 2014 Jan; 42(1):124-39. PubMed ID: 24178577
[TBL] [Abstract][Full Text] [Related]
55. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
56. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
[TBL] [Abstract][Full Text] [Related]
57. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
58. Proteomics analysis of tissue small extracellular vesicles reveals protein panels for the reoccurrence prediction of colorectal cancer.
Ji L; Fu J; Hao J; Ji Y; Wang H; Wang Z; Wang P; Xiao H
J Proteomics; 2021 Oct; 249():104347. PubMed ID: 34384913
[TBL] [Abstract][Full Text] [Related]
59. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
[TBL] [Abstract][Full Text] [Related]
60. CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b.
Zhang Q; Zheng Y; Liu J; Tang X; Wang Y; Li X; Li H; Zhou X; Tang S; Tang Y; Wang X; He H; Li T
Cell Death Dis; 2023 Jan; 14(1):24. PubMed ID: 36639711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
